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pursue any additional requirements of Food and Drug
Administration that might lead to such labelling. Thus,
though this process exists it has rarely been used to
alter labelling.
Recognising this failure and with the encourage›
ment of the American Academy of Pediatrics, the FDA
Modernization Act of 1997 (FDAMA) provided that
manufacturers of drugs under patent could seek a six
month patent extension for performing studies
leading to labelling in children. Although six months
may seem short, the financial windfall for many of
these drugs is a strong incentive. Some manufacturers
may choose to wait until patents are about to expire to
initiate these studies. Concerns were raised over this
approach when omeprazole (Prilosec, Losec) was stud›
ied in children after its success was well established in
adults and received a patent extension giving them a
potential “two billion dollar sales windfall.”5 This gives
them more opportunity to pick drugs that are sure to
be profitable to study in children. Unfortunately, drugs
with limited potential for financial gain will not be
studied even though they may have a potential benefit
for children.
To level the playing field further, the Food and
Drug Administration rules went into effect in 1999
permitting the agency to mandate paediatric studies if
the product is likely to be used in a substantial number
of children.5 They may also decide that a meaningful
therapeutic benefit to children exists and mandate
studies.6 As these regulations come into effect,
President Bush is considering reversing these require›
ments under pressure from the pharmaceutical indus›
try. We can only hope that the best interests of children
are put first in his consideration.
The outcome of these changes at the Food and
Drug Administration thus far is slightly encouraging.
Several new drugs have included studies in children
leading to labelling. On the other hand, some
disappointing decisions have hurt the process. For
example, recombinant activated protein C was
approved for adults and had ample safety and
pharmacokinetic data in children but was rejected for
paediatric labelling on the presumption that mecha›
nisms of severe sepsis were sufficiently different in chil›
dren that efficacy could not be extrapolated from the
data in adults. As a paediatrician, I find that an extreme
view that may inhibit the use of a potentially beneficial
therapy for children. Furthermore, there is increasing
pressure by healthcare insurance providers to limit
reimbursement only to labelled indications and popu›
lations. High technology drugs such as this come at a
high price and limitations on payment will not help
children.
Off label use of drugs is expanding for the paediat›
ric population rather than decreasing.7 The use of psy›
chotropic drugs has literally exploded in behavioural
and psychiatric practices in the United States. In some
cases the off label use may be based on both age and
diagnosis such as in attention deficit in children.
Unfortunately it will take a concerted effort and a great
deal of funding to correct this problem. For new drugs
reaching the market we can hope that the Food and
Drug Administration will continue to receive the
authority to mandate consideration of children in
addition to the carrot of patent extension to promote
appropriate labelling for children and other disenfran›
chised populations.
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The FDA has announced that it will suspend the enforcement of
the paediatric rule for two years while it examines its necessity.
(Pediatric News 2002;36(4):60.)
1 ‘t Jong GW, Eland IA, Sturkenboom MCJM, van den Anker JN, Stricker
BHCh. Unlicensed and off label prescription of drugs to children: popu›
lation based cohort study. BMJ:2002;324:1313›4.
2 Bücheler R, Schwab M, Mörike K, Kalchthaler B, Mohr H, Schröder H, et
al. Off label prescribing to outpatient children in Germany: a retrospec›
tive data base analysis. BMJ:2002;324:1311›2.
3 Schirm E, Tobi H, ‘t Jong GW. Unlicensed and off label drug use by chil›
dren in the community: cross sectional study. BMJ 2002;324:1312›3.
4 American Academy of Pediatrics Committee on Drugs. Unapproved uses
of approved drugs: the physician, the package insert, and the Food and
Drug Administration: subject review. Pediatrics 1996;98:118›23.
5 The Pediatric Exclusivity Provision: January 2001 Status Report to Con›
gress: www.fda.gov/cder/pediatric/reportcong01.pdf. (Accessed 10 Mar
2002.)
6 Landers SJ. Extension expected for pediatric drug law. American Medical
News, 4 June 2001.
7 Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the
prescribing of psychotropic medications to preschoolers. JAMA
2000;283:1059›60.
Quality care at the end of life
Should be recognised as a global problem for public health and health systems
Worldwide, 56 million people die each year,85% of these in developing countries.1 2 Yetlittle is known about the quality of care they
receive at the end of their lives. The movement for
improving the quality of care at the end of life is
primarily focused on industrialised countries. Until it is
seen as a global problem for public health and health
systems, efforts to improve it will not make much
impact in the world.
Public health
Quality of care at the end of life is a global public
health problem because of the large number of people
involved. If each death affects five other people in
terms of giving informal care and grieving relatives
and friends, the total number of people affected each
year by end of life care is about 300 million, or 5% of
the world’s population.
Some of the interventions that could be used to
improve care are in the realm of public health. These
include large scale, culturally specific, educational pro›
grammes for public health workers and the public;
population based strategies to destigmatise death and
put it into the mainstream of health systems; and
changes in social policies in relation to care for
orphans.
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Improving care at the end of life will require
research in public health. Of the many papers
published on care at the end of life in the past decade,
only a few have dealt with this problem in developing
countries.
Health systems
Care at the end of life is a global problem for health
systems because most people die in hospitals—at least
in some countries3; research in palliative care has
involved the organisation and delivery of palliative care
services4; techniques such as rapid cycle change have
been applied to improve the quality of care at the end
of life; and accountability of managers of health
systems and healthcare professionals is an important
part of the solution.
More fundamentally, however, care at the end of
life is a problem for health systems because improving
its quality will rely on health information. Information
about quality is recognised as a central concern of
the health system, as exemplified by the report card
movement. We have never seen information on care
at the end of life on quality report cards. Why? Just
as clinicians once put dying patients in the room at
the end of the hall and never made rounds on
them, health policy makers have kept the issue of
care at the end of life outside the mainstream of their
concerns.
There are data on mortality and other measures of
quality of care, but there is no information on quality
indicators for end of life care in the statistical
appendices of the Word Health Organization’s
world health reports. There were also no measures
related to end of life care among the performance
measures of health systems in the world health report
for 2000.
Even in Canada, which is recognised as a leader in
health information, no information is available on the
quality of care at the end of life for the 222 000 Cana›
dians who die each year. In 2000 the Canadian senate
recommended that the Canadian Institute for Health
Information develop indicators for end of life care.5 To
our knowledge this is the first such recommendation,
but it has not yet been implemented.
Two caveats
Simply applying Western perspectives on end of life
care to developing nations is unrealistic and apt to fail.
Any effort to improve the quality of care at the end of
life in developing countries must be culturally based
and include people from these countries. For example,
traditional healers may serve as effective champions of
care at the end of life in some settings because they are
closely connected with shared values and community
beliefs.
We live in a world where the life expectancy is
about 80 years and rising for people in many
developed countries and about 40 years and probably
falling for people in some developing countries.6 We
have been asked, “In such an unjust world, where
apparently the lives of many people in developing
countries do not matter, why should their deaths?” This
sets up a false dichotomy. If someone is condemned to
a premature death because of the injustice of global
health inequality, it is doubly unjust for that person to
be condemned to an agonising death racked by
preventable pain.
Way forward
We can improve the quality of care at the end of life in
the world by (1) Recognising care at the end of life as a glo›
bal problem for public health and health systems—The very
conceptualisation of care at the end of life as a problem
for global public health and health systems brings this
issue into the mainstream of global public health. It
then also falls under the scope of the WHO’s initiatives
on the performance of health systems.
(2) Capacity strengthening—We have recently out›
lined a vision for strengthening capacity in global
health ethics, and this too should include attention to
care at the end of life.7 The Open Society Institute has
made a major impact on capacity for addressing care at
the end of life in the United States through its project
on death in America. The time is right for a global
effort at strengthening capacity in care at the end of life
by creating a project on death in the world.
(3) Information strategies—No national health system
to our knowledge systematically collects information
on the quality of care at the end of life of its citizens.
Countries with well developed health information
structures, such as Canada, could make an important
contribution. Case studies of developing countries
would provide useful evidence on which to base any
global effort to improve end of life care. We will know
that the problem of care at the end of life has truly
been globalised when the WHO devotes a world health
report to care at the end of life and when indicators for
such care are routinely included in its annual
indicators of the performance of health systems.
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